(A) Policy Statement

All Pulmonary Function staff, after an appropriate physician order is received, will use the following guidelines for the safe delivery of Pentamidine aerosols. Appropriate orders should be accompanied by physician’s documentation that active tuberculosis has been ruled out.

The order must include pre-Pentamidine treatment with a unit dose bronchodilator.

Pentamidine will be given via a Respigard II Nebulizer for the treatment or prevention of Pneumocystis carinii pneumonia.

Those staff members who are pregnant or trying to conceive may elect to refrain from exposure of the Pentamidine drug.

(B) Purpose of Policy

To assure that Pentamidine is delivered in a manner that is considered safe and effective to the patient, while assuring that the medication is not aerosolized into the atmosphere.

(C) Procedure

1. Pentamidine aerosols shall only be administered in the Pulmonary Function Lab Pentamidine aerosolization booth. The following equipment should be gathered before beginning procedure:
   a. AeroStar portable aerosol protection cart
   b. Oxygen flowmeter with nipple adapter
   c. A Respigard II nebulizer system. Treatment will be administered in accordance with manufacturer’s insert.
   d. Standard nebulizer, for bronchodilator administration
   e. Unit dose Proventil
   f. One 300 mg vial of Pentamidine
   g. One 10ml vial of sterile water, USP
h. 12ml syringe with 18 gauge needles
i. 50 psi gas source

2. Review the orders to determine that the physician has documented that active tuberculosis has been ruled out.

3. Obtain order and administer unit dose bronchodilator prior to pentamidine treatment.

4. For Outpatients: order should also include a frequency for up to 12 months and allergy review.

5. The medication will be diluted as prescribed by the ordering physician.

6. Prior to initiation of the Pentamidine treatment, family members will be required to leave the room and the door will be closed.

7. The patient will be monitored by the Pulmonary Function staff member for any adverse reactions including: coughing, bronchospasm or increased pulse rate. If any adverse reactions are observed, the treatment will be stopped and the physician notified.

<table>
<thead>
<tr>
<th>Approved by:</th>
<th>Review/Revision Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Bonamigo</td>
<td>03/19/1990 08/05/2008</td>
</tr>
<tr>
<td>Director, Respiratory Care</td>
<td>10/06/1992 06/30/2011</td>
</tr>
<tr>
<td>Daniel L Barbee, RN, BSN, MBA</td>
<td>05/26/1993 02/27/2014</td>
</tr>
<tr>
<td>Director of Nursing/Chief Nursing Officer</td>
<td>05/11/1995 09/12/1996</td>
</tr>
<tr>
<td></td>
<td>7/27/1999 05/30/2002</td>
</tr>
<tr>
<td></td>
<td>08/11/2005</td>
</tr>
</tbody>
</table>

Next Review Date: February 27, 2017

It is the responsibility of the reader to verify with the responsible agent that this is the most current version of the policy.